R&D policy, agency costs and innovation in personalized medicine

Journal of Health Economics

Volumn 28, Issue 5, 2009, Pages 950-962

  Yin, Wesley ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Health policy; Pharmaceutical innovation; Technological change

Indexed keywords

BIOTECHNOLOGY; DESIGN; DRUG DEVELOPMENT; HEALTH POLICY; INCENTIVE; INNOVATION; MEDICINE; PHARMACEUTICAL INDUSTRY; RESEARCH AND DEVELOPMENT; SCIENCE AND TECHNOLOGY; TECHNOLOGICAL DEVELOPMENT;

ARTICLE; DISEASE CONTROL; DRUG INDUSTRY; DRUG MARKETING; FINANCIAL MANAGEMENT; HEALTH CARE POLICY; HEALTH ECONOMICS; MEDICAL TECHNOLOGY;

DRUG INDUSTRY; HEALTH POLICY; HUMANS; INDIVIDUALIZED MEDICINE; MODELS, ECONOMETRIC; ORPHAN DRUG PRODUCTION; RARE DISEASES; RESEARCH SUPPORT AS TOPIC; UNITED STATES;

EID: 70349880348     PISSN: 01676296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhealeco.2009.06.011     Document Type: Article

References (25)

1. Arrow K. Economic Welfare and the Allocation of Resources for Invention. Economics of Technological Change (1962), N. Rosenberg, Harmondsworth, Penguin
2. Aspinall M.G., and Hamermesh R.G. Realizing the promise of personalized medicine. Harvard Business Review 85 10 (2007)
3. Cameron A.C., and Trivedi P.K. Regression Analysis of Count Data (1998), Cambridge University Press
4. Collins F., Green E., et al. A vision for the future of genomics research. Nature 422 (2003) 835-847
5. Couzin J. To what extent are genetic variation and personal health linked?. Science 309 5731 (2005) 81
6. DiMasi J., Hansen R., et al. The price of innovation: new estimates of drug development costs. Journal of Health Economics 22 (2003) 151-185
7. Finkelstein A. Static and dynamic effect of health policy: evidence from the vaccine industry. Quarterly Journal of Economics 119 2 (2004) 527-564
8. Garrison L.P., and Austin M.J. Linking pharmacogenetics-based diagnostics and drugs for personalized medicine. Health Affairs 25 5 (2006) 1281-1290
9. Haffner M.E., Whitley J., et al. Two decades of orphan product development. Nature Reviews Drug Discovery 1 (2002) 821-825
10. Hall B., and Van Reenen J. How effective are fiscal incentives for R&D? A review of the evidence. Research Policy 29 4-5 (2000) 449-470
11. Hall B. The financing of research and development. Oxford Review of Economic Policy 18 1 (2002) 35-51
12. Hausman J., Hall B., et al. Econometric models for count data with application to patents-R&D relationship. Econometrica 52 (1984) 909-938
13. House of Representatives Subcommittee Report. Preliminary Report of the Survey on the Drugs for Rare Diseases. Subcommittee on the Health and the Environment (1982), Government Printing Office, DC
14. Kremer M. Creating markets for new vaccines. Part I: rationale. In: Jaffe A.B., Lerner J., and Stern S. (Eds). Innovation Policy and the Economy vol. 1 (2001), MIT Press
15. Lazear, E., 1996. Incentives in basic research. NBER working paper no. 5444.
16. Lichtenberg, F., Virabhak, S., 2002. Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as "Equipment for your Health". NBER working paper no. 9351.
17. Lichtenberg, F., Waldfogel, J., 2003. Does misery love company? Evidence from pharmaceutical markets before and after the Orphan Drug Act. NBER working paper no. 9750.
18. Maeder T. The orphan drug backlash. Scientific American 288 5 (2003) 87-90
19. Rin-Laures L.-H., and Janofsky D. Recent developments concerning the orphan drug act. Harvard Journal of Law & Technology 4 (1991) 269-297 (Spring)
20. Rohde D.D. The orphan drug act: an engine of innovation? At what cost?. Food and Drug Law Journal 55 1 (2000) 125-143
21. Salop S. Monopolistic competition with outside goods. Bell Journal of Economics 10 1 (1979) 141-156
22. Senate Subcommittee Hearings S.2060. Subcommittee on Antitrust, Monopolies and Business Rights (1992), Government Printing Office, US
23. Wooldridge J. Quasi-likelihood methods for count data. In: Pesaran M.H., and Schmidt P. (Eds). Handbook of Applied Econometrics vol. 2 (1997), Blackwell, Oxford pp. 352-406
24. Wooldridge J. Distribution-free estimation of some non-linear panel data models. Journal of Econometrics 90 (1999) 77-97
25. Yin W. Market incentives and pharmaceutical innovation. Journal of Health Economics 27 4 (2008) 1060-1077